Companies in #Targeted Oncology
Found 2 companies operating in this sector.
ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.
Curis is a clinical-stage oncology biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor being studied in combination with ibrutinib in hematologic malignancies (including the TakeAim CLL and TakeAim Lymphoma studies) and as a monotherapy in solid tumors. The company has historically worked on multiple first-in-class targeted cancer therapeutics in partnership with major pharma. Curis completed a 1-for-5 to 1-for-25 reverse stock split effective in July 2026 to maintain Nasdaq listing compliance, with split-adjusted trading beginning shortly thereafter.